GABRIEL OLIVEIRA SAWAKUCHI
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Linear Energy Transfer | 11 | 2019 | 98 | 3.630 |
Why?
|
| Protons | 16 | 2022 | 473 | 3.370 |
Why?
|
| Radiometry | 15 | 2021 | 980 | 2.560 |
Why?
|
| Carbon | 6 | 2021 | 149 | 2.130 |
Why?
|
| Proton Therapy | 16 | 2022 | 1577 | 1.700 |
Why?
|
| Monte Carlo Method | 12 | 2019 | 671 | 1.650 |
Why?
|
| Aluminum Oxide | 4 | 2014 | 10 | 1.360 |
Why?
|
| Luminescent Measurements | 3 | 2012 | 148 | 1.180 |
Why?
|
| Radiation Dosage | 7 | 2018 | 1014 | 1.110 |
Why?
|
| Photons | 5 | 2021 | 507 | 1.010 |
Why?
|
| Phantoms, Imaging | 10 | 2020 | 1271 | 0.980 |
Why?
|
| Particle Accelerators | 4 | 2017 | 352 | 0.970 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 663 | 0.940 |
Why?
|
| Magnetic Fields | 3 | 2019 | 31 | 0.890 |
Why?
|
| DNA Damage | 4 | 2022 | 1954 | 0.840 |
Why?
|
| Radiotherapy, High-Energy | 4 | 2013 | 295 | 0.830 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 7 | 2021 | 2370 | 0.830 |
Why?
|
| Luminescence | 3 | 2019 | 44 | 0.680 |
Why?
|
| DNA End-Joining Repair | 1 | 2019 | 86 | 0.670 |
Why?
|
| Homologous Recombination | 1 | 2019 | 185 | 0.650 |
Why?
|
| Diamond | 1 | 2017 | 3 | 0.640 |
Why?
|
| Electrical Equipment and Supplies | 1 | 2017 | 9 | 0.640 |
Why?
|
| Algorithms | 5 | 2016 | 3890 | 0.610 |
Why?
|
| Genes, BRCA1 | 2 | 2019 | 387 | 0.610 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 459 | 0.600 |
Why?
|
| Radiotherapy | 4 | 2019 | 1824 | 0.590 |
Why?
|
| Cell Death | 1 | 2019 | 671 | 0.590 |
Why?
|
| Time-Lapse Imaging | 1 | 2016 | 18 | 0.560 |
Why?
|
| Absorption, Radiation | 1 | 2016 | 10 | 0.560 |
Why?
|
| Optical Phenomena | 2 | 2012 | 26 | 0.540 |
Why?
|
| Fluorescence | 1 | 2016 | 195 | 0.540 |
Why?
|
| Radiosurgery | 2 | 2023 | 1330 | 0.540 |
Why?
|
| Radiation Tolerance | 4 | 2022 | 629 | 0.470 |
Why?
|
| Water | 6 | 2017 | 361 | 0.440 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 750 | 0.430 |
Why?
|
| Heavy Ions | 1 | 2011 | 1 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 7702 | 0.410 |
Why?
|
| Models, Theoretical | 4 | 2019 | 785 | 0.380 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1910 | 0.370 |
Why?
|
| Radiotherapy, Image-Guided | 5 | 2020 | 304 | 0.360 |
Why?
|
| Radiotherapy Dosage | 10 | 2021 | 3842 | 0.350 |
Why?
|
| Cell Survival | 3 | 2021 | 3045 | 0.350 |
Why?
|
| Thermoluminescent Dosimetry | 2 | 2019 | 77 | 0.340 |
Why?
|
| Thorax | 2 | 2019 | 213 | 0.300 |
Why?
|
| Relative Biological Effectiveness | 3 | 2022 | 219 | 0.290 |
Why?
|
| Calibration | 3 | 2019 | 337 | 0.280 |
Why?
|
| Computer Simulation | 5 | 2018 | 1529 | 0.270 |
Why?
|
| Electrons | 3 | 2017 | 168 | 0.250 |
Why?
|
| Scattering, Radiation | 3 | 2010 | 316 | 0.240 |
Why?
|
| Head | 2 | 2020 | 249 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5319 | 0.230 |
Why?
|
| Alpha Particles | 2 | 2023 | 26 | 0.230 |
Why?
|
| Rad51 Recombinase | 2 | 2022 | 126 | 0.220 |
Why?
|
| Boron Neutron Capture Therapy | 1 | 2022 | 10 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 7551 | 0.210 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 925 | 0.200 |
Why?
|
| Germ-Line Mutation | 3 | 2021 | 1046 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 4 | 2023 | 5061 | 0.200 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2019 | 316 | 0.180 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2022 | 363 | 0.180 |
Why?
|
| Optically Stimulated Luminescence Dosimetry | 1 | 2019 | 16 | 0.180 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2021 | 202 | 0.180 |
Why?
|
| Time Factors | 4 | 2019 | 12926 | 0.180 |
Why?
|
| Equipment and Supplies | 1 | 2019 | 48 | 0.180 |
Why?
|
| Radiation Oncologists | 1 | 2019 | 29 | 0.180 |
Why?
|
| Film Dosimetry | 1 | 2019 | 59 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2019 | 52 | 0.170 |
Why?
|
| Radiobiology | 1 | 2019 | 56 | 0.170 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 14551 | 0.170 |
Why?
|
| Space Flight | 2 | 2013 | 158 | 0.170 |
Why?
|
| Isoquinolines | 1 | 2019 | 116 | 0.170 |
Why?
|
| Radiation-Protective Agents | 1 | 2019 | 128 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 11538 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 1301 | 0.160 |
Why?
|
| Molecular Imaging | 1 | 2019 | 185 | 0.160 |
Why?
|
| Humans | 25 | 2023 | 261506 | 0.150 |
Why?
|
| Pancreas | 1 | 2021 | 718 | 0.150 |
Why?
|
| Air | 1 | 2017 | 63 | 0.150 |
Why?
|
| Neck | 1 | 2020 | 383 | 0.150 |
Why?
|
| Chemoradiotherapy | 2 | 2016 | 1946 | 0.150 |
Why?
|
| Glycine | 1 | 2019 | 289 | 0.150 |
Why?
|
| Scintillation Counting | 1 | 2018 | 97 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 545 | 0.140 |
Why?
|
| Gene Silencing | 1 | 2019 | 837 | 0.140 |
Why?
|
| Energy Transfer | 1 | 2016 | 35 | 0.140 |
Why?
|
| Cell Tracking | 1 | 2016 | 38 | 0.140 |
Why?
|
| Neoplasms | 4 | 2023 | 15193 | 0.130 |
Why?
|
| Reference Standards | 1 | 2016 | 339 | 0.130 |
Why?
|
| Models, Statistical | 2 | 2013 | 1171 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2016 | 199 | 0.120 |
Why?
|
| Spleen | 1 | 2016 | 676 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 7789 | 0.120 |
Why?
|
| Organs at Risk | 1 | 2016 | 514 | 0.120 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 1202 | 0.120 |
Why?
|
| Quality Control | 3 | 2020 | 457 | 0.120 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 6009 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 769 | 0.110 |
Why?
|
| Extraterrestrial Environment | 1 | 2013 | 8 | 0.110 |
Why?
|
| Mars | 1 | 2013 | 5 | 0.110 |
Why?
|
| Cell Line | 1 | 2021 | 5114 | 0.110 |
Why?
|
| Radiation | 1 | 2013 | 20 | 0.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 1724 | 0.110 |
Why?
|
| X-Rays | 2 | 2022 | 146 | 0.110 |
Why?
|
| Histones | 1 | 2019 | 1466 | 0.100 |
Why?
|
| Immunoassay | 1 | 2013 | 216 | 0.100 |
Why?
|
| Light | 1 | 2012 | 245 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2019 | 1411 | 0.100 |
Why?
|
| Mutation | 3 | 2021 | 15179 | 0.100 |
Why?
|
| Lung | 2 | 2019 | 3151 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2019 | 1589 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 10035 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2019 | 5637 | 0.090 |
Why?
|
| Equipment Design | 3 | 2020 | 1204 | 0.090 |
Why?
|
| Cosmic Radiation | 1 | 2009 | 15 | 0.090 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2022 | 430 | 0.080 |
Why?
|
| BRCA1 Protein | 2 | 2021 | 493 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2023 | 1021 | 0.080 |
Why?
|
| Genes, BRCA2 | 2 | 2021 | 309 | 0.080 |
Why?
|
| DNA Repair | 3 | 2022 | 1872 | 0.080 |
Why?
|
| Uncertainty | 1 | 2010 | 320 | 0.080 |
Why?
|
| Models, Anatomic | 1 | 2009 | 154 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 15694 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2027 | 0.070 |
Why?
|
| Neutrons | 2 | 2019 | 117 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 5767 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 2104 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 902 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2020 | 2292 | 0.060 |
Why?
|
| Radioisotopes | 1 | 2023 | 177 | 0.050 |
Why?
|
| Induction Chemotherapy | 2 | 2016 | 669 | 0.050 |
Why?
|
| Boron Compounds | 1 | 2022 | 59 | 0.050 |
Why?
|
| Phenylalanine | 1 | 2022 | 142 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 152 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4557 | 0.050 |
Why?
|
| Physics | 1 | 2021 | 44 | 0.050 |
Why?
|
| Biology | 1 | 2021 | 75 | 0.050 |
Why?
|
| Equipment Failure Analysis | 2 | 2013 | 329 | 0.050 |
Why?
|
| Remote Sensing Technology | 1 | 2019 | 12 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2022 | 285 | 0.050 |
Why?
|
| Germ Cells | 1 | 2021 | 335 | 0.040 |
Why?
|
| Ataxia Telangiectasia | 1 | 2019 | 62 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 479 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 430 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2588 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2022 | 37905 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2017 | 44 | 0.040 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2019 | 226 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 383 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 726 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2019 | 414 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 388 | 0.040 |
Why?
|
| Female | 7 | 2023 | 141928 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 1020 | 0.030 |
Why?
|
| Syndrome | 1 | 2019 | 1351 | 0.030 |
Why?
|
| Breath Holding | 1 | 2015 | 44 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.030 |
Why?
|
| Male | 6 | 2023 | 123000 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 978 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 486 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 2693 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 4971 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2021 | 32848 | 0.030 |
Why?
|
| Aged | 4 | 2023 | 70117 | 0.030 |
Why?
|
| Atrazine | 1 | 2013 | 6 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 29902 | 0.030 |
Why?
|
| Chaperonin 60 | 1 | 2013 | 47 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2013 | 128 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 15862 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1331 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 2316 | 0.020 |
Why?
|
| Radiography | 1 | 2015 | 1904 | 0.020 |
Why?
|
| Absorption | 1 | 2010 | 81 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2019 | 2086 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1350 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2009 | 61 | 0.020 |
Why?
|
| Systems Integration | 1 | 2010 | 76 | 0.020 |
Why?
|
| Adaptation, Biological | 1 | 2009 | 49 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1987 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 1489 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3719 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 838 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3441 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5710 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6207 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 9244 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 4975 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2010 | 288 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 6942 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 5539 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 4988 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 6682 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 77950 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 3552 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 13658 | 0.020 |
Why?
|
| Middle Aged | 3 | 2019 | 86204 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12221 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 5270 | 0.020 |
Why?
|
| Apoptosis | 1 | 2019 | 7591 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 10001 | 0.010 |
Why?
|
| Texas | 1 | 2010 | 6311 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 34495 | 0.010 |
Why?
|
| United States | 1 | 2013 | 15433 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 59536 | 0.010 |
Why?
|